In addition, the decline in plasma levels of CD31+EMP further supports the concept that IFN-β1a exerts stabilizing effect on the cerebral endothelial cells in pathogenesis of MS.

We have observed a decrease in plasma CD31+EMP following initiation of intramuscular treatment of MS patients with IFN-β1a, 30 µg weekly. This decrease reached significance at week 12 and became ...